Surrozen (SRZN) COO Charles Williams Buys $14K of Stock

Charles Williams, the Chief Operating Officer of Surrozen, Inc. (NasdaqCM: SRZN), recently bought 1,666 shares of the company. The transaction took place on June 15, 2026, at an average price of $8.11 per share, amounting to a total value of $13,511.26. This purchase was not part of a pre-arranged trading plan.

Insider Buying and Selling at Surrozen, Inc.

On June 15, 2026, several key executives at Surrozen, Inc. made notable share purchases. Charles Williams, the COO, acquired 1,666 shares at $8.11 each. CEO Craig Parker also bought 1,622 shares at the same price. Additionally, Andrew Pedrum Maleki, the CFO, purchased 607 shares at $19.01. These transactions were not part of any pre-planned trading programs.

Other Institutional Activity in Surrozen, Inc.

Several institutional investors have also been active in Surrozen, Inc. COLUMN GROUP LLC increased its holdings by 65,600 shares, bringing its total to 1,916,950 shares valued at approximately $55.8 million. TCG CROSSOVER MANAGEMENT, LLC added 1,473,101 shares to its portfolio, now holding 1,473,101 shares worth about $42.9 million. BOXER CAPITAL MANAGEMENT, LLC significantly boosted its stake by 350,168 shares, ending with 766,318 shares valued at $22.3 million. In contrast, STEMPOINT CAPITAL LP reduced its position by 94,127 shares, now holding 525,639 shares worth $13.5 million.

Surrozen, Inc. Stock Up 37.5%

Shares of Surrozen, Inc. (NasdaqCM: SRZN) are currently trading at $23.14. The company has a market capitalization of approximately $264.1 million. Surrozen is not currently profitable, so it has no meaningful P/E ratio. The stock's beta is 0.506, indicating lower volatility compared to the market. Over the past year, the shares have ranged from $8.00 to $35.00, with a 50-day moving average of $27.95 and a 200-day moving average of $21.21. The company maintains a strong liquidity position with a current ratio of 11.91 and a quick ratio of 11.70.

Analysts Set New Price Targets

On May 7, 2026, HC Wainwright & Co. maintained its 'buy' rating for Surrozen with a price target of $44. Earlier this year, Cantor Fitzgerald initiated coverage with a 'buy' rating and a $40 target on February 19. The consensus among analysts is a 'buy' rating, with an average target price of $42.50 based on four analyst opinions.

About Surrozen, Inc.

Surrozen, Inc. is a biotechnology company based in South San Francisco, California. It focuses on developing innovative therapies by modulating the Wnt pathway for tissue repair. The company's lead products are antibody-based therapeutics targeting diseases in the eye, intestine, liver, and other organs. Surrozen collaborates with Boehringer Ingelheim and TCGFB to advance its research and development efforts. Founded in 2015, the company employs around 44 people and is led by CEO Craig C. Parker.

Bottom Line

Charles Williams' recent stock purchase highlights insider confidence in Surrozen, Inc. Investors often track such moves as potential indicators of future company performance. It's important to remember that these insider transactions are disclosed after the fact and do not necessarily predict future stock movements.